{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["avutometinib","sotorasib"],["avutometinib","sotorasib","defactinib"]],"indication":"KRAS G12C mutant non-small cell lung cancer","name":"RAMP 203","nct_id":"NCT05074810","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ramp-203-nct05074810. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RAMP203","arms":[{"description":"To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients","label":"avutometinib (VS-6766)+sotorasib","type":"EXPERIMENTAL"},{"description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients","label":"avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve","type":"EXPERIMENTAL"},{"description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients","label":"avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed","type":"EXPERIMENTAL"},{"description":"To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients","label":"avutometinib (VS-6766)+sotorasib+defactinib","type":"EXPERIMENTAL"},{"description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients","label":"avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive","type":"EXPERIMENTAL"},{"description":"To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients","label":"avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed","type":"EXPERIMENTAL"}],"collaborators":["Amgen"],"completion_date":{"date":"2027-04","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer","KRAS Activating Mutation"],"enrollment":{"count":153,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"avutometinib and sotorasib","otherNames":["AMG 510","LUMAKRAS™","VS-6766"],"type":"DRUG"},{"name":"avutometinib and sotorasib and defactinib","otherNames":["AMG 510","LUMAKRAS™","VS-6766","VS-6063"],"type":"DRUG"}],"last_update":"2026-01-12","lead_sponsor":"Verastem, Inc.","official_title":"A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib","timeFrame":"From start of treatment to confirmation of RP2D; 28 days"},{"measure":"Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A","timeFrame":"From start of treatment to confirmation of response; 16 weeks"}],"references":[{"citation":"Coma S, Musteanu M, Malvezzi CC, Jamieson RR, Patrucco E, Mira A, Dilly J, Li Z, Fernandez-Rodriguez A, Lopez-Garcia A, Aguirre AJ, Barbacid M, Ambrogio C, Pachter JA. FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. Sci Transl Med. 2026 Sep 30;18(869):eaea4608. doi: 10.1126/scitranslmed.aea4608. Epub 2026 Sep 30.","pmid":"42814800","type":"DERIVED"}],"start_date":{"date":"2022-04-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","url":"https://clinicaltrials.gov/study/NCT05074810"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ramp-203-nct05074810"}